129 related articles for article (PubMed ID: 31628379)
1. Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates.
Eriksson O; Velikyan I; Haack T; Bossart M; Evers A; Laitinen I; Larsen PJ; Plettenburg O; Takano A; Halldin C; Antoni G; Johansson L; Pierrou S; Wagner M
Sci Rep; 2019 Oct; 9(1):14960. PubMed ID: 31628379
[TBL] [Abstract][Full Text] [Related]
2. First-in-class positron emission tomography tracer for the glucagon receptor.
Velikyan I; Haack T; Bossart M; Evers A; Laitinen I; Larsen P; Plettenburg O; Johansson L; Pierrou S; Wagner M; Eriksson O
EJNMMI Res; 2019 Feb; 9(1):17. PubMed ID: 30771019
[TBL] [Abstract][Full Text] [Related]
3. Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.
Eriksson O; Haack T; Hijazi Y; Teichert L; Tavernier V; Laitinen I; Berglund JE; Antoni G; Velikyan I; Johansson L; Pierrou S; Wagner M; Tillner J
Sci Rep; 2020 Oct; 10(1):16758. PubMed ID: 33028880
[TBL] [Abstract][Full Text] [Related]
4. Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.
Eriksson O; Velikyan I; Haack T; Bossart M; Laitinen I; Larsen PJ; Berglund JE; Antoni G; Johansson L; Pierrou S; Tillner J; Wagner M
J Nucl Med; 2021 Jun; 62(6):833-838. PubMed ID: 33097629
[TBL] [Abstract][Full Text] [Related]
5. Automated GMP-Compliant Production of [
Wagner M; Doverfjord JG; Tillner J; Antoni G; Haack T; Bossart M; Laitinen I; Johansson L; Pierrou S; Eriksson O; Velikyan I
Pharmaceuticals (Basel); 2020 Jul; 13(8):. PubMed ID: 32752075
[No Abstract] [Full Text] [Related]
6. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs.
Nalin L; Selvaraju RK; Velikyan I; Berglund M; Andréasson S; Wikstrand A; Rydén A; Lubberink M; Kandeel F; Nyman G; Korsgren O; Eriksson O; Jensen-Waern M
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1800-10. PubMed ID: 24643781
[TBL] [Abstract][Full Text] [Related]
8. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
[TBL] [Abstract][Full Text] [Related]
9. Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.
Chang R; Zhang X; Qiao A; Dai A; Belousoff MJ; Tan Q; Shao L; Zhong L; Lin G; Liang YL; Ma L; Han S; Yang D; Danev R; Wang MW; Wootten D; Wu B; Sexton PM
J Biol Chem; 2020 Jul; 295(28):9313-9325. PubMed ID: 32371397
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4.
Selvaraju RK; Velikyan I; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Korsgren O; Eriksson O
J Nucl Med; 2013 Aug; 54(8):1458-63. PubMed ID: 23761918
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
12. Species differences in pancreatic binding of DO3A-VS-Cys
Eriksson O; Rosenström U; Selvaraju RK; Eriksson B; Velikyan I
Acta Diabetol; 2017 Nov; 54(11):1039-1045. PubMed ID: 28891030
[TBL] [Abstract][Full Text] [Related]
13. The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice.
Beaudry JL; Kaur KD; Varin EM; Baggio LL; Cao X; Mulvihill EE; Stern JH; Campbell JE; Scherer PE; Drucker DJ
Mol Metab; 2019 Apr; 22():37-48. PubMed ID: 30772257
[TBL] [Abstract][Full Text] [Related]
14. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents.
Kim T; Holleman CL; Nason S; Arble DM; Ottaway N; Chabenne J; Loyd C; Kim JA; Sandoval D; Drucker DJ; DiMarchi R; Perez-Tilve D; Habegger KM
Diabetes; 2018 Nov; 67(11):2157-2166. PubMed ID: 30150304
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O
Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864
[TBL] [Abstract][Full Text] [Related]
18. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
19. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
